Presentation is loading. Please wait.

Presentation is loading. Please wait.

Virology Education, P: +31302307140 F: +31302307148, E: 1- 3 June 2011, Milan Marriott Hotel, Milan,

Published byErnest Chandler Modified over 8 years ago

Similar presentations

Presentation on theme: "Virology Education, P: +31302307140 F: +31302307148, E: 1- 3 June 2011, Milan Marriott Hotel, Milan,"— Presentation transcript:

1 Virology Education, P: +31302307140 F: +31302307148, E: info@virology-education.com www.virology-education.com 1- 3 June 2011, Milan Marriott Hotel, Milan, Italy Again in 2011: Pre-workshop educational course for practicing clinicians

2 Virology Education, P: +31302307140 F: +31302307148, E: info@virology-education.com www.virology-education.com David Back, MD, University of Liverpool, UK: Drug Drug Interactions Marco Cavaleri, MD, EMA, London, UK: Regulatory issues with the clinical testing of the new HCV compounds Marion Peters, MD, University of California, San Francisco, USA HIV/HBV coinfection in chronic kidney disease Jürgen Rockstroh, MD, University of Bonn, Germany Acute HCV: overview ongoing cohort studies Mark Sulkowski, MD, Johns Hopkins University, USA Expert’s overview of the latest data presented at the EASL Kenneth Sherman, MD, PhD, University of Cincinnati College of Medicine, USA Expert’s overview of the latest data presented at the CROI Stefan Zeuzem, MD, J.W. Goethe University Hospital, Frankfurt, Germany New DAA’s for Treatment of Hepatitis C: Promises and Challenges CONFIRMED SPEAKERS

3 Virology Education, P: +31302307140 F: +31302307148, E: info@virology-education.com www.virology-education.com REGISTRATION AND ABSTRACT SUBMISSION Abstract topics: - Immunology of HCV - Interactions between antiretrovirals and anti-HBV and anti-HCV agents - Treatment issues on HCV-HIV - Treatment issues on HBV-HIV - HCV resistance - HBV resistance - New anti-HCV drugs - Non invasive assessment of liver fibrosis - Liver steatosis - Liver toxicity - Liver cancer - Liver transplantation - Delta Hepatitis Deadline abstract submission: 1 April 2011 Registration timeline: Early : 1 Feb. - 15 March 2011 Regular : 16 March - 15 April 2011 Late : 16 April - 15 May 2011 On-Site : 1, 2 and 3 June 2011

Download ppt "Virology Education, P: +31302307140 F: +31302307148, E: 1- 3 June 2011, Milan Marriott Hotel, Milan,"

Similar presentations

STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV Douglas.

STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV Douglas.
European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.

European Guidelines for the HIV Treatment Esteban Martínez Infectious Diseases Unit Hospital Clínic University of Barcelona Barcelona SPAIN.
When, how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20.

When, how and which patient to treat with HBV infection. David Mutimer Queen Elizabeth Hospital Birmingham, England. BSG Post-graduate Course March 20.
Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV.
Washington D.C., USA, 22-27 July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
Hepatitis C among people who inject drugs (PWID) in India: High burden but limited access to care Shruti H. Mehta, PhD MPH Professor, Johns Hopkins Bloomberg.

Hepatitis C among people who inject drugs (PWID) in India: High burden but limited access to care Shruti H. Mehta, PhD MPH Professor, Johns Hopkins Bloomberg.
Chris Fraser, MD Medical Director, Cool Aid Community Health Centre Clinical Faculty, UBC Faculty of Medicine.

Chris Fraser, MD Medical Director, Cool Aid Community Health Centre Clinical Faculty, UBC Faculty of Medicine.
HIV and Hepatitis B or C co-infection Preliminary results of survey.

HIV and Hepatitis B or C co-infection Preliminary results of survey.
Challenges in HIV-HBV co-infection

Challenges in HIV-HBV co-infection
BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A. www.bordernet.eu www.aidshilfe-potsdam.de.

BORDERNETwork Training on HIV and HBV Co-Infections Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A.
Liver Disease and Thalassaemia George Constantinou.

Liver Disease and Thalassaemia George Constantinou.
N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER CROI 2015: What’s New in Hepatitis? Nina Kim, MD Associate Professor of Medicine Division of Allergy &

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER CROI 2015: What’s New in Hepatitis? Nina Kim, MD Associate Professor of Medicine Division of Allergy &
Fig 1: HIV-1/HCV and HIV-1/HBV Co-Infection/Co- Culture Systems Philippe A. Gallay 1, Udayan Chatterji 1, Michael Bobardt 1, Daren Ure 2, Dan Trepanier.

Fig 1: HIV-1/HCV and HIV-1/HBV Co-Infection/Co- Culture Systems Philippe A. Gallay 1, Udayan Chatterji 1, Michael Bobardt 1, Daren Ure 2, Dan Trepanier.
Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.

Senate Health Care Committee Briefing: Hepatitis C Treatment Dan Lessler, MD Chief Medical Officer November 20, 2014.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.

Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.

Slide 1 of 8 From MG Peters, MD, at Los Angeles, CA: April 22, 2013, IAS-USA. IAS–USA Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor.
SAVE THE DATE 1 st International Workshop on HIV & Aging Deadline for applications to register: 7 August 2010 Deadline for abstract submission: 7 August.

SAVE THE DATE 1 st International Workshop on HIV & Aging Deadline for applications to register: 7 August 2010 Deadline for abstract submission: 7 August.
Hepatitis C Virus Infection Hepatitis C Virus Infection Burden of Disease in United States New infections (cases)/year 1985-89242,000 200520,000 Persons.

Hepatitis C Virus Infection Hepatitis C Virus Infection Burden of Disease in United States New infections (cases)/year , ,000 Persons.
F/C AETC Faculty HIV HCV Thursday, March 12, 2015 | 1:30pm EDT Medical Facilitator/Didactic Presenter Todd S. Wills, MD University of South Florida Case.

F/C AETC Faculty HIV HCV Thursday, March 12, 2015 | 1:30pm EDT Medical Facilitator/Didactic Presenter Todd S. Wills, MD University of South Florida Case.

Similar presentations

Ads by Google